देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
OMBITASVIR; PARITAPREVIR; RITONAVIR
ABBVIE CORPORATION
J05AP53
OMBITASVIR, PARITAPREVIR AND RITONAVIR
12.5MG; 75MG; 50MG
TABLET
OMBITASVIR 12.5MG; PARITAPREVIR 75MG; RITONAVIR 50MG
ORAL
56 (1 MONTH CARTON, 28 PACKS, 2 TABLETS PER PACK)
Prescription
HCV Protease Inhibitors
Active ingredient group (AIG) number: 0357510001; AHFS:
CANCELLED POST MARKET
2018-07-30
_TECHNIVIE Product Monograph _ _ _ _Page 1 of 67 _ _Date of Revision: February 13, 2018 and Control No. 211480 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TECHNIVIE ™ ombitasvir/paritaprevir/ritonavir film-coated tablets (12.5/75/50 mg) Antiviral Agent Date of Preparation: October 20, 2015 Date of Previous Revision: August 10, 2017 AbbVie Corporation Date of Revision: 8401 Trans-Canada Highway February 22, 2018 St-Laurent, Qc H4S 1Z1 Submission Control No: 211480 _TECHNIVIE Product Monograph _ _ _ _Page 2 of 67 _ _Date of Revision: February 13, 2018 and Control No. 211480 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................12 DRUG INTERACTIONS ..................................................................................................16 DOSAGE AND ADMINISTRATION ..............................................................................35 OVERDOSAGE ................................................................................................................37 ACTION AND CLINICAL PHARMACOLOGY ............................................................37 STORAGE AND STABILITY ..........................................................................................43 SPECIAL HANDLING INSTRUCTIONS .......................................................................43 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................43 PART II: SCIEN पूरा दस्तावेज़ पढ़ें